

[illegible]

10

15

20

25

30

35

8. The method of claim 3, wherein said TNF binding protein and said fas fusion protein are administered in a pharmaceutically acceptable carrier.

5

10

15

20

25

30

35

16. The use of Claim 15, wherein the anti-inflammatory drug is methotrexate.

17. The use according to claim 16 wherein the methotrexate in the medicament is up to about 25 mg.

5 19. The use according to claims 15 through 17
wherein said methotrexate is administered orally.

10

15

20

24. The use of according to Claim 21, wherein
25 the anti-inflammatory drug is a fas fusion protein.

30

add β^2